# A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

> **NCT04685226** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 310 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** ICP-723

## Key facts

- **NCT ID:** NCT04685226
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-27
- **Primary completion:** 2028-01-25
- **Final completion:** 2028-02-25
- **Target enrollment:** 310 (ESTIMATED)
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04685226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04685226, "A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04685226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*